What Was Approved?
On July 31, 2025, the U.S. Food and Drug Administration approved Vizz (aceclidine ophthalmic solution) for the treatment of presbyopia in adults.
Presbyopia is an age-related condition that makes it harder to focus on nearby objects.
How Does Vizz Work?
Vizz is a cholinergic agonist.
Aceclidine causes the pupil to become smaller, which can improve near vision by increasing depth of focus.
How Is Vizz Used?
The FDA-approved dosing is:
One drop in each eye, followed by a second drop in each eye 2 minutes later, once daily.
Vizz is for ophthalmic use only.
What Did the Clinical Trials Show?
FDA approval was supported by three clinical trials.
Two six-week trials evaluated effectiveness in 466 adults with presbyopia, while a separate 26-week study involving 361 patients provided additional safety information.
In the efficacy trials, Vizz improved near visual acuity compared with the control treatments used in the studies.
These results do not guarantee the same degree of improvement for every patient.
What Are Important Safety Considerations?
Patients should use Vizz exactly as directed and discuss eye conditions or other ophthalmic medicines with their eye-care professional.
Because pupil constriction can affect vision under certain lighting conditions, patients should be cautious with activities that require clear vision until they know how the medicine affects them.
Does Vizz Permanently Correct Presbyopia?
No.
Vizz is a medication used to temporarily improve near vision. It does not permanently reverse the age-related changes that cause presbyopia.
Bottom Line
Vizz (aceclidine ophthalmic solution) is an FDA-approved once-daily eye drop for adults with presbyopia.
It provides a non-surgical option for improving near vision, but patients should follow the product-specific dosing instructions and discuss appropriate use with an eye-care professional.
Sources
- U.S. Food and Drug Administration (FDA) — Drug Trials Snapshot: Vizz.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2025.
- U.S. Food and Drug Administration (FDA) — Vizz Approval Package, July 31, 2025.